Follow hydroxyapatite up the value chain and it ends in a syringe. Calcium hydroxylapatite (CaHA) dermal fillers sell for hundreds of dollars per millilitre \u2014 the same mineral family that ships in drums, repositioned as an injectable that claims to do more than fill: to \u201cbiostimulate\u201d the skin into making its own collagen.<\/p>\n
In 2023, a systematic review in Frontiers in Medicine<\/em> went looking for the mechanism studies behind the marketing. The funnel is the story: \u201cof 2,935 identified citations, 12 studies were included for final analysis.\u201d Within those twelve, \u201ccollagen production was reported by nine studies, cell proliferation by four, elastic fibers and\/or elastin by four, and three studies on angiogenesis.\u201d And the sentence that should hang over every sales deck in the category: \u201conly seven studies had a control group.\u201d<\/p>\n The signal that survives is real but narrow. The best-documented effect is neocollagenesis \u2014 one controlled study measured collagen type III expression rising from 2.38 \u00b1 0.81 to 5.26 \u00b1 1.20 four months after injection (p < 0.0001). Beyond collagen, elastin and some angiogenesis, the reviewers\u2019 verdict is flat: \u201cthe majority of the studies had methodological limitations,\u201d and evidence on the wider mechanism claims is limited and inconclusive.<\/p>\n Twelve from 2,935 is worth pausing on. A citation count that large reads as a vast literature, yet after the review applied its criteria, the mechanistic core was twelve papers, seven with controls. That is how an evidence base can feel deep while being shallow \u2014 volume of discussion standing in for volume of data. Anyone doing diligence on an ingredient claim eventually learns to run the same funnel: not \u201chow many papers mention this\u201d but \u201chow many measured it, against a control, in something resembling the product as sold.\u201d<\/p>\n Three reasons. First, market navigation: CaHA is where hydroxyapatite\u2019s highest margins live, and anyone mapping demand for the mineral should know that this segment\u2019s scientific foundation is twelve papers deep \u2014 a market priced like settled science and evidenced like an early one. Second, the asymmetry it reveals: the burden of proof in aesthetics has, historically, been lighter than the marketing implies. A new supplier imagining an impossible evidence bar should recalibrate \u2014 the bar the incumbents actually cleared is visible, and it is not high. Third, the caution it teaches: category-wide mechanism claims (\u201cbiostimulation\u201d) can outrun the data for years. Borrowing that language for adjacent products \u2014 topicals, oral care, supplements \u2014 imports a debt of proof the twelve studies cannot service.<\/p>\nWhy does a raw-material buyer care about someone else\u2019s syringe?<\/h2>\n